Biotech Funding Cycle

The biotech funding cycle has crossed from multi-year contraction into selective bifurcation, with late-stage and commercial-scale biotech companies accessing capital and deploying R&D spending at levels that are now materially funding instrument and service demand, while early-stage biotech and academic research remain constrained. CRL's trailing-twelve-month small and mid-cap biotech funding of nearly $100 billion, combined with IQV's reported $35 billion in EBP funding in Q2 2026 (more than double Q2 2025), is directly converting into RFP flow, bookings acceleration, and revenue translation across CRO and life sciences tools vendors. However, this recovery masks a two-tier market: PACB explicitly repositioning away from academic and government customers toward clinical accounts due to 'funding environment in the United States, contributing to elongated sales cycles'; BIO and TECH reporting ongoing pressure in academic research spending; and ARE documenting the fifth consecutive year of biotech bear market with life science VC fundraising at its lowest level since 2016. Large-cap pharma and biotech (MRK, VRTX, PFE, BMY) are deploying $15+ billion in aggregate capital for clinical-stage acquisitions, functioning as the primary exit path for VC-backed companies in a selective funding environment. The forward indicator is whether early-stage biotech funding velocity sustains through H2 2026 or whether the current recovery remains confined to clinical validation and commercial execution—a distinction that will determine whether instrument vendors see continued organic growth or reversion to constrained capex cycles.